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Abstract: Heparin is a sulfated glycan widely used as anticoagulant in 
medicine. Mallard Blue (MalB), a small cationic dye developed in our 
laboratories, is able to detect heparin in serum and plasma in a dose-
response manner, with performance superior to its direct competitors. 
However, many aspects of MalB/heparin binding still remain to be explored 
which, once solved, may foster the clinical use of MalB. Among these, the 
characterization of the energetics that drives the MalB/heparin binding 
process, the competition for MalB binding by other polyanions (e.g., 
negatively-charged surfactant micelles), and the interaction of MalB with 
serum proteins are of particular interest. This work fills this gap by 
means of a combination of experimental investigations (UV-visible 
spectroscopy and isothermal titration calorimetry), and computational 
approaches based on molecular dynamics (MD) simulation techniques. In 
combination, the results obtained show that MalB efficiently binds to 
both heparin and SDS, with the binding being enthalpic in nature; yet, 
SDS is able to extract MalB from its complex with heparin when the 
surfactant is in its self-assembled form, the driving force underlying 
SDS-induced MalB/heparin de-complexation being entropic in nature as the 
two enthalpies of binding effectively cancel each other out. Once bound 
to SDS, the dye remains electrostatically bound to the micellar surface 
and does not penetrate the micelle palisade layer, as verified by steered 
molecular dynamics/umbrella sampling simulations. Finally, the affinity 
of MalB for human serum albumin (HSA), the most abundant plasma protein, 
is found to be lower than that for heparin, confirming the ability of the 
dye to work in complex physiological environments. 
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Abstract 
Heparin is a sulfated glycan widely used as anticoagulant in medicine. Mallard Blue (MalB), a small cationic dye 
developed in our laboratories, is able to detect heparin in serum and plasma in a dose-response manner, with 
performance superior to its direct competitors. However, many aspects of MalB/heparin binding still remain to 
be explored which, once solved, may foster the clinical use of MalB. Among these, the characterization of the 
energetics that drives the MalB/heparin binding process, the competition for MalB binding by other polyanions 
(e.g., negatively-charged surfactant micelles), and the interaction of MalB with serum proteins are of particular 
interest. This work fills this gap by means of a combination of experimental investigations (UV-visible 
spectroscopy and isothermal titration calorimetry), and computational approaches based on molecular 
dynamics (MD) simulation techniques. In combination, the results obtained show that MalB efficiently binds to 
both heparin and SDS, with the binding being enthalpic in nature; yet, SDS is able to extract MalB from its 
complex with heparin when the surfactant is in its self-assembled form, the driving force underlying SDS-
induced MalB/heparin de-complexation being entropic in nature as the two enthalpies of binding effectively 
cancel each other out. Once bound to SDS, the dye remains electrostatically bound to the micellar surface and 
does not penetrate the micelle palisade layer, as verified by steered molecular dynamics/umbrella sampling 
simulations. Finally, the affinity of MalB for human serum albumin (HSA), the most abundant plasma protein, is 
found to be lower than that for heparin, confirming the ability of the dye to work in complex physiological 
environments. 
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Highlights 
 
x Mallard Blue (MalB) is one of the best dyes for heparin sensing  
x MalB binding to heparin is enthalpy-driven, with a small entropic penalty 
x SDS micelles bind MalB with an affinity similar to heparin, and can decomplex MalB from heparin as a result 
of a favorable entropic contribution 
x MalB binds only weakly to plasma proteins supporting its use in complex biological fluids 
  
Highlights (for review)
1. Introduction 
Heparin, a linear polysaccharide consisting of repeating units of 2-O-sulfated iduronic acid 
and 6-O-sulfated, N-sulfated glucosamine (IdoA(2S)-GlcNS(6S), Fig. 1 left) - is one of the most 
charge-dense naturally occurring polyanion in biological systems [1]. Heparin has been used 
as an anticoagulant since 1935 to both treat and prevent the deep vein thrombosis that can 
result from large surgery, blood transfusions, or dialysis. As a result of its clinical importance, 
there has been a surge of interest in developing heparin sensors which can directly detect 
heparin chains within a complex biological sample (that is, measure a true concentration) 
rather than rely on an activity measurement within plasma or serum (units of anticoagulant 
activity). Perhaps the leading strategy has been the development of cationic indicator dyes 
which can quickly report on heparin spectroscopically. In this respect, several molecules such 
as Azure A [2,3], Alcian Blue [4], Methylene Blue [5], Heparin Blue and Heparin Orange [6] Ȃ 
which all exhibit UV response to heparin Ȃ have historically been employed. Yet, while these 
cationic dyes work well in noncompetitive environments, many of them lose efficiency a) in 
the presence of other agents (e.g., plasma proteins) that directly interfere with their heparin 
noncovalent binding and b) as electrolytic competition increases.  
In the quest for alternative heparin sensors that can quantitatively and reliably perform under 
physiological conditions, in 2013 our group synthesized Mallard Blue (MalB, Fig. 1 right), a 
thionine-di-arginine molecule that can be readily obtained via a coupling reaction between 
Tri-Boc-protected arginine and thionine acetate followed by Boc deprotection [7].  
 
Fig_1.tiff  
Fig. 1. Molecular model of the predominant average repeat unit of heparin (left) and of Mallard Blue (MalB, 
right). In each structure, the molecules are shown as atom-colored sticks-and balls (C, gray; O, red; N, blue; S, 
yellow; H, white). Na+ and Cl- counterions are portrayed as purple and green spheres, respectively.  
 
In the same study [7], we established that MalB is able to detect heparin in serum and plasma 
in a dose-response manner, its superior performance with respect to the direct competitor 
Azure A, its heparin specificity and, likely its most interesting and promising property, its 
resistance to high ionic strength (e.g., 150 mM NaCl), despite the fact that electrostatic forces 
govern its interaction with the polyanion. Interestingly, the excellent sensing properties of 
MalB under physiologically conditions were the subject of a positive News and Views article 
which appeared in Nature Chemistry in the same year [8].  
Under this promising scenario, however, many aspects still remain to be explored which, once 
solved, may foster the clinical use of MalB. Among these, the characterization of the energetics 
that drive the MalB/heparin binding process, the competition for MalB binding by other 
polyanions (e.g., negatively-charged surfactant micelles), and the interaction of MalB with 
serum proteins still remain to be performed. This work aims to fill this gap by means of a 
combination of experimental investigations, based on UV-visible spectroscopy and isothermal 
titration calorimetry (ITC), and computational approaches, relying on molecular dynamics 
(MD) simulation techniques. 
Specifically, since the interaction of MalB with heparin has never been fully characterized so 
far, either from a spectrometric or from a thermodynamic point of view, we first report and 
discuss the spectroscopic and thermodynamic behavior for MalB binding to heparin and 
compare them with that obtained for negatively-charged micelles generated by the self-
assembly of a conventional anionic surfactant sodium dodecyl sulfate (SDS). The idea 
underlying these experiments is that, given the predictable electrostatic nature of 
heparin/MalB interaction, highly oppositely-charged micelles may compete with the 
polysaccharide and promote MalB dissociation with subsequent sequestration. Indeed, 
micelle-ǲextractionǳbound ligands from polyanions is a competitive phenomenon, 
particularly in the case of DNA (e.g., drugs/mutagens DNA de-intercalation). However, the 
energy cost for such processes is still not properly understood. Therefore, we deemed it very 
interesting to investigate this particular aspect in case of MalB. These experiments are 
paralleled by computational investigations based on steered molecular dynamics [8-12], 
which allow us to mimic MalB unbinding from heparin and subsequent association with SDS 
micelles at a molecular level.  
Next, we present the results of binding thermodynamics of MalB to the most representative 
plasma protein, human serum albumin (HSA), and resort again to atomistic MD simulations in 
the Molecular Mechanics/Poisson-Boltzmann framework of theory [see 13-16 and references 
therein] to identify the molecular determinants underlying its interaction with the heparin 
sensor. 
 
2. Materials and Methods 
All chemicals were purchased from Sigma Aldrich, and used without further purification. 
Mallard Blue, heparin and human serum albumin were available from our previous work [7, 
17-22]. 
2.1. UV-visible spectroscopy 
UV-visible absorbance was measured on a DeNovix DS11-FX spectrophotometer (DeNovix 
Inc., Wilmington, DE, USA). All MalB solutions were incubated at 50°C for 24 hours prior to 
use and stored in the dark. For the MalB/heparin binding, solutions of MalB (125 PM) in 150 
mM NaCl and 10 mM Tris HCl were incubated with solutions of heparin at progressively 
increasing concentrations in the same buffer (9, 17, 34, 67.5, 125, 250, 500, and 1000 PM). For 
MalB/SDS binding, a series of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, and 5 mM) were added to 
the MalB solutions (125 PM, 150 mM NaCl/10 mM Tris HCl). The range of SDS concentrations 
was selected in order to consider surfactant systems below and above their CMC (1.2 mM, see 
below). For SDS/MalB binding in the presence of heparin, a presoaked MalB/heparin solution 
was prepared (125 PM MalB/150 PM heparin, which ensures complete binding, [7]) and a 
series of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, 5, and 10 mM) were added. All experiments were 
carried out at 25 °C and performed in triplicate. The absorbance at 615 nm was recorded after 
each addition.  
2.2. Isothermal titration calorimetry (ITC) 
2.2.1. Binding of MalB to heparin, SDS micelles, and SDS-driven MalB extraction from heparin. 
ITC experiments were conducted using MicroCal PEAQ-ITC calorimeter (Malvern, UK) at 25°C.  ? ? ?ɊǤ All experiments were conducted in a backward manner, that is, 
by step-by-step injections of a constant volume of concentrated heparin or SDS solutions into 
the calorimetric cell containing buffer (150 mM NaCl/10 mM Tris HCl, pH 7.4), or buffered 
solutions of MalB, respectively. For SDS-driven MalB extraction from heparin assay, a buffered 
MalB solution in large excess of heparin (to ensure complete MalB/heparin binding) in the 
cell was used instead. Specifically, for SDS CMC determination, a  ?Ɋ of SDS 
solution (60 mM) was repeatedly injected (37 times) into the reaction cell at 150 s intervals. 
For MalB binding by heparin, a polyanion solution (2 mM) was  ? ? ?Ɋ
at 150 s intervals, while the MalB concentration in the calorimeter cell was 125 PM. For 
MalB/SDS binding, a 1 mM solution of MalB in the cell was titrated  ? ? ?Ɋ
a 300 mM SDS solution at 150 s intervals, such that the concentration of SDS was always 
above the CMC, and allowing us to make the assumption that the micelles remained intact 
throughout the experiment. For the MalB/heparin extraction by SDS micelles, the calorimeter 
cell was filled with a pre complexed MalB/heparin solution (1 mM/5 mM), and titration was 
performed with a 300 mM solution   ȋ ? ?    ? Ɋ     ? ? ? ȌǤ All 
solutions and buffers were degassed for 30 min at room temperature under stirring at 750 
rpm prior to each experiment. After careful washing, the cell was pre-rinsed with a portion of 
the buffer, MalB, or MalB/heparin solutions, respectively.  Upon filling the cell and syringe, 
stirring was turned on and each system was allowed to thermally equilibrate for 30 minutes. 
The heat signal resulting from mixing, dilution effects and liquid friction were further 
confirmed by control experiments (data not shown); accordingly, they were subtracted from 
the relevant data sets to yield the corrected integrated data. All experiments were run in 
triplicate. 
2.2.2. Binding of MalB to HSA 
For this ITC experiment, the instrument cell was filled with a 50 PM buffered (150 mM 
NaCl/10 mM Tris HCl, pH 7.4) solution of HSA. Titration was performed with a 500 PM 
buffered solution of MalB, added in 19 portions of 1 PL, with time intervals of 150 s. 
2.3. Molecular simulations 
2.3.1. Model building, refinement and simulation details 
All simulations discussed in this work were carried out using the AMBER16 suite of programs 
[23], the GAFF force field [24] and performed with the GPU version of pmemd (pmemd.cuda) 
in AMBER16 on our MOSE GPU/CPU cluster. AMBER16 is the state of the art simulation 
platform universally recognized and adopted for simulating biological systems and their 
interactions with soft matter and small molecules. A SDS micelle (consisting of 60 surfactant 
monomers) was built using the Micelle Maker server [25], and optimized, following a 
consolidated procedure for self-assembly nanostructures [17-22,26-30]. The initial, optimized 
structures of heparin, MalB, heparin/MalB complex and ligand-free human serum albumin 
(HSA) were taken from our previous work [7,9,14,17-22]. 
Docking of MalB to HSA was accomplished by adapting a procedure described in details in 
[13,15,16,31-34 and references therein]. Briefly, docking experiments were performed with 
Autodock 4.2/Autodock Tools 1.4.6 [35]. The resulting docked conformations were clustered 
and visualized; then, only the molecular conformation satisfying the combined criteria of 
having the lowest (i.e., more favorable) Autodock energy and belonging to a highly populated 
cluster was selected to carry forward for further modeling. The MalB/HSA complex obtained 
from the docking procedure was further refined in Amber 16 using the quenched molecular 
dynamics (QMD) method as previously described [36-38].  
The optimized structures of the SDS micelle, heparin/MalB complex, and MalB/HSA complex 
were immersed in a box of TIP3P water molecules [39]. The choice of the TIP3P model is 
based on the fact that it is the best compromise between accuracy description of the water 
behavior and computational time required; moreover, it has been specifically developed and 
parametrized to simulate hydrated environments of biological macromolecules, surfactants 
and small organic molecules. The dimensions of each simulation box were chosen in order to 
ensure a 1 nm solvation shell around each solute structure. Suitable amounts of Na+ and Cl- 
ions required to achieve solution neutrality and realize a physiological ionic strength of 0.15 
M were added to each system. The resulting hydrated structures were then subjected to an 
initial Steepest Descent (SD)/Conjugated Gradient (CG) minimization with 5.0 kcal/(mol ǒ 2) 
restraint on the solute (solvent relaxation), followed by another round of CG minimization 
without restraints in order to eliminate all bad contacts between water molecules and each 
solute. 
Next, each minimized structure was subjected to molecular dynamics (MD) simulations in the 
canonical (NVT) ensemble. During these 100 ps of MD, each system was gradually heated and 
relaxed to 25°C. The SHAKE algorithm [40] was applied to all covalent bonds involving 
hydrogen atoms. An integration time step of 2 fs was adopted together with the Langevin 
thermostat for temperature regulation (collision frequency = 2.0 ps-1) [41]. The final heating 
step was followed by 50 ns of MD equilibration in the isochoric/isothermal (NPT) ensemble. 
Pressure control was exerted by coupling the system to a Berendsen barostat (pressure 
relaxation time 2 ps) [42]. The Particle Mesh Ewald (PME) method [43Ȑ   - - ? ?ǒ . To generate the starting configuration for steered molecular dynamics simulations 
(Section 2.3.2), a frame of the SDS micelle and of the MalB/heparin complex was extracted 
from the corresponding equilibrated MD trajectories. The entire equilibrated MD run of the 
MalB/HSA complex was used in the determination of dye/protein free energy of binding 
(section 2.3.3).  
2.3.2. Steered molecular dynamics (SMD) and Umbrella sampling (US) simulations 
The unbinding process of MalB from heparin and the binding event between MalB and the 
SDS micelle were simulated using a combination of steered molecular dynamics (SMD) [9-12] 
and umbrella sampling (US) simulations [44]. In the first case, the MalB/heparin complex 
structure extracted from the corresponding equilibrated MD simulations was solvated with a 
TIP3P water [39] cubic box, and ions and counter ions were added to neutralize the system 
and reach the physiological ionic strength (150 mM NaCl). In the second case, the optimized 
SDS micelle and a molecule of MalB were placed in simulation cell at an initial distance of 
approximately 5 nm. The resulting system was solvated using the same solvent system 
adopted for the MalB/heparin complex.  After each system equilibration (1 ns of NVT/NPT 
MD simulation), SMD runs were performed, and were next used to extract the initial 
coordinates for umbrella sampling simulations along the unbinding/binding pathway, 
respectively. A pulling force with a virtual spring constant of 50 kcal (mol Å2)-1 was imposed 
on the ligand center of mass and the center of mass of the SDS micelle/heparin in the 
unbinding/binding simulations, and the speed was 5 Å ns-1 based on considerations of 
sampling accuracy and computational efficiency. The reaction coordinate for the umbrella 
sampling simulations, ], is defined as the distance between the MalB center of mass (COM) 
and the COM of heparin when pulling MalB out of the heparin complex, and between the COM 
of MalB and the COM of the SDS micelle when pulling MalB towards the SDS micelle. During 
both SMD and US simulations, the heparin/SDS micelle initial structures were retained in 
their initial configurations applying a small constraint force of 5 kcal (mol Å2)-1 on the 
coordinates of the heavy atoms of heparin for the unbinding simulations, and on the two 
terminal carbons of each SDS chain in the binding simulations.  
To perform US simulations, MalB position probability distributions along the reaction 
coordinate were extracted from the corresponding SMD simulations. US method adopts a 
biased potential function imposed on the structure generated by the SMD along ], according 
to the following equation: ǯȋ]) = U(]) + W(])           (1) 
where U(]) is the potential function and W(]) is a quadratic-form weighting function: 
W(]) = K (] Ȃ ]0)2/2           (2) 
in which K is the harmonic force constant and ]0 is the harmonic potential center.  
In this work, each path was subdivided in 80 windows (spacing 0.8 Å), enough to push the 
MalB inside the SDS micelle in the binding simulation, and to bring the MalB fairly far away 
from heparin in the unbinding one. An equilibration time of 1 ns was adopted for each 
window, and data collection lasted 4 ns per window, yielding a total data collection time of 
320 ns. A value of K = 5 kcal/mol was set to restrain ] in all simulations. The weighted 
histogram analysis method (WHAM) [45] was used to unbias simulations and to retrieve the 
PMF. Errors were estimated by the bootstrapping analysis implemented in the WHAM 
package [46]. 
2.3.3. Mallard Blue/human serum albumin free energy of binding calculations 
The free energy of binding between MalB and HSA was obtained by applying the Molecular 
Mechanics/Poisson Boltzmann Surface Area (MM/PBSA) approach [13-16]. This 
computational technique employs snapshots taken from MD trajectories to estimate the 
average interaction energies based on the solute molecular mechanics internal energy and 
solvation energy (constituting the enthalpic term), and entropy variation. The solvation term 
is calculated solving the Poisson-Boltzmann equation [47] while 'Gnp can be obtained via the 
semi-empirical expression [48]: 'Gnp = J × SASA + E, in which SASA is the solvent accessible 
surface area of the molecule, J is the surface tension parameter (0.00542 kcal/Å2/mol), and E 
= 0.92 kcal/mol. Finally, the entropic contribution is calculated via normal mode of harmonic 
frequencies [49] obtained from a subset of minimized snapshots taken from the 
corresponding MD trajectories. For the analysis of the energy of interaction between HSA and 
MalB, energy values were averaged over 200 frames taken during equally spaced time 
intervals along the last 15 ns of the MD production steps. Normal mode analysis was carried 
out on a subset of 15 minimized MD snapshots evenly extracted from the relevant trajectory 
time frame used for energy calculations. 
 
3. Results and discussion 
3.1. UV-visible spectroscopy assays 
The first experiment was carried out to investigate the binding of MalB to SDS using UV-
visible spectroscopy. The insert in Fig. 2A shows a representative set of the UV-visible spectra 
of MalB in the absence and in the presence of increasing concentration of SDS (the full curve 
set is shown in Fig. SI1). As already reported in our previous investigation [7], MalB in 150 
mM NaCl/10 mM Tris HCl buffer produces an absorption peak at 615 nm; upon addition of 
SDS, the maximum absorbance initially decreases and then increases with increasing 
surfactant concentration. This non-monotonic behavior can be better appreciated by plotting 
the relative change in absorption intensity (I/I0, where I and I0 are the peak absorption values 
in the presence and absence of SDS, respectively), as illustrated in Fig. 2A.  
 
Fig_2.tiff 
Fig. 2. Relative change in UV-visible absorbance intensity (I/I0) of (A) MalB as a function of SDS concentration, 
(B) MalB as a function of heparin concentration, and (C) heparin/MalB complex as a function of SDS 
concentration in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). In all experiments, [MalB] = 
125 PM. The corresponding absorbance spectra is shown in the relative Figure insets. For clarity, only a 
representative set of the corresponding absorbance spectra is shown in the inset of panel A (see Fig. SI1 for the 
full curve set). 
 
We see from this Figure that, for small additions of SDS (i.e., [SDS] < CMCSDS), I/I0 attains 
values lower than 1. This initial quenching of the MalB UV-visible absorbance intensity can be 
attributed to the interaction of MalB molecules with SDS surfactant in its monomeric form, in 
agreement with previous literature reports for other cationic dyes, e.g., Nile Blue [50] and 
phenosafranine [51]. As [SDS] approaches CMCSDS in the adopted buffer conditions (CMCSDS = 
1.02 mM in 150 mM NaCl/10 mM Tris HCl, see Fig. SI2), I/I0 rapidly increases and then levels-
off for surfactant concentration values > 3 mM (Fig. 2A). The substantial increase in the 
absorption spectrum intensity of MalB at higher SDS concentrations is indicative of a tighter 
binding of the dye with SDS micelles driven by electrostatic forces between the highly 
negative micellar surface and the positive charges present on the molecular dye, which places 
MalB into a different environment. [52-54].  
Figure 2B shows the profile of I/I0 for the interaction between MalB and heparin. In this case, 
the initial electrostatic polyanion/MalB interactions result in a plummet of the MalB UV-
visible absorption intensity, followed by a considerably less pronounced decrease of I/I0 vs. 
[Heparin] once all polysaccharide binding sites become saturated by dye binding (i.e., 125 PM 
< [Heparin] < 250 PM). Interestingly, a similar behavior has been reported for Nile Blue 
binding to DNA [50,55], suggesting that common mechanisms may underlie the interactions 
of different cationic molecules with the two seemingly different, negatively charged 
biomacromolecules. 
When SDS solutions are added to a pre-formed MalB/heparin complex, the UV-visible spectra 
reported in Fig. 2C are obtained. The initially flat curve of I/I0 as a function of [SDS] rapidly 
increases for [SDS]  ? CMCSDS and ultimately plateaus for [SDS] > 2.5 PM. In this last surfactant 
concentration range, the absorption intensity values correspond to those observed for MalB 
in the pure SDS micellar environment, strongly supporting the notion that the dye, no longer 
bound to heparin, has been complexed by the surfactant self-assembled spherical micelles1. 
3.2. Isothermal titration calorimetry (ITC) assays 
To experimentally quantify - for the first time - the binding thermodynamics between MalB 
and heparin, to confirm the spectroscopic evidences of MalB/SDS micelle interactions, and to 
verify the ability of SDS micelles to extract MalB from heparin, we resorted to ITC 
measurements, as shown in Fig. 3. 
The binding of MalB to heparin (Fig. 3A) is strongly exothermic ('Hb = -9.36 ± 0.24 kcal/mol), 
while a small, negative entropy change opposes dye/polyanion interaction (T'Sb = -1.47 
kcal/mol). Accordingly, MalB/heparin complex formation is thermodynamically favored, with 
                                                        
1 It should be noted that the I/I0 value appears larger in Fig. 2C than 2A because the starting point of the 
experiment, and hence the value of I0, is different. In Fig. 2A the starting point I0 value corresponds to 
uncomplexed MalB, whereas in Fig. 2B, the starting point I0 corresponds to MalB bound to heparin. 
a free energy of binding 'Gb value of Ȃ 7.89 kcal/mol (see Fig. 4A). The large, negative 
enthalpy variation observed in MalB/heparin complex formation is comparable to that 
observed for, e.g., small molecule/DNA or drug/protein binding [9-22,26-34], and can be 
ascribed to the formation of a network of stabilizing non-specific intermolecular interactions 
(i.e., electrostatic, hydrogen bonds, salt bridges,) between the two molecular entities. The 
small and unfavorable entropic term is also quite characteristic of these processes, since 
macromolecule/ligand hydrophobic interactions and water/ion release into the bulk cannot 
compensate for the loss in degree of freedom of experienced by the dye/polyanion upon 
binding.  
 
     Fig_3.tiff 
Fig. 3. Representative integrated ITC profiles for titration of (A) MalB with heparin, (B) MalB with SDS, and (C) 
MalB/heparin complex with SDS in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). T = 25 °C. 
The solid red lines are data fitting with a sigmoidal function. The inserts in each panel show the corresponding 
ITC raw data. All experiments were run in triplicate. 
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Fig. 4. ITC-derived thermodynamic parameters ('Hb, full color; T'Sb, square pattern; 'Gb, diagonal line pattern) 
for (A) MalB binding with heparin, (B) MalB binding with SDS, and (C) extraction of MalB from the MalB/heparin 
complex with SDS.  
 
The interaction of SDS micelles with MalB (Fig. 3B) is also enthalpically driven ('Hb = -9.06 ± 
0.19 kcal/mol) and, as for MalB/heparin binding, is characterized by a small entropic penalty 
(T'Sb = - 1.64 kcal/mol), resulting in an overall favorable binding free energy 'Gb of -7.42 
kcal/mol (Fig. 4B). The fact that the MalB/SDS has a substantial enthalpic nature supports the 
fact that hydrophobic interactions contribute only in minimal part to this specific dye/micelle 
binding, and electrostatic forces play the leading role. This, in turn, suggests that, once bound, 
MalB prefers to reside in the micellar outer Stern layer rather than locating itself into the 
palisade layer or deep inside the micellar core (see Section 3.3).  
Finally, ITC measurements reveal that, when SDS micelles are added to a MalB/heparin 
complex solution, the thermodynamic nature of the underlying process is opposite with 
respect to that described above (Fig. 3C). Indeed, while an almost negligible, endothermic 
contribution is measured ('Hb = + 0.23 ± 0.04 kcal/mol), the driving force for MalB extraction 
from heparin by SDS micelles results from the strong, positive entropic variation (T'Sb = + 
6.25 kcal/mol), which ultimately determines the overall negative value of the free energy ('Gb 
= -6.02 kcal/mol) (see Fig. 4C). The increase in system entropy can be attributed to several, 
concomitant factors, including i) an increase in degrees of freedom of heparin after MalB 
complexation, ii) the disruption of hydrogen bonds and electrostatic interactions between 
water molecules/counterions and the micellar surface upon MalB binding, and iii) their 
subsequent release into the bulk solvent.  
In order to model the process of MalB extraction from heparin by the anionic surfactant 
micelles the following two-step model can be assumed: 
 ሺܯ݈ܽܤȀܪ݁݌ܽݎ݅݊ሻ௛௬ௗ௥ ֖  ሺܯ݈ܽܤሻ௛௬ௗ௥ ൅ ሺܪ݁݌ܽݎ݅݊ሻ௛௬ௗ௥       (3) ሺܵܦܵ݈݈݉݅ܿ݁݁ݏሻ௛௬ௗ௥ ൅ ሺܯ݈ܽܤሻ௛௬ௗ௥ ֖  ሺܯ݈ܽܤ ܵܦܵ݈݈݉݅ܿ݁݁ݏ ? ሻ௛௬ௗ௥      (4) 
 
in which all different species are considered in their hydrated form in the relevant buffer. The 
approach is obviously a rough simplification of reality, as i) it assumes that Eqs. (3) and (4) 
represent independent events and ii) additional steps associated with these two major events 
either do not contribute significantly to the overall process or their effects are accounted for 
by the equilibrium thermodynamic parameters. Under this hypothesis, and with the further 
assumption that each binding process is reversible, the unbinding of MalB from heparin (i.e., 
Eq. (3)) should then be characterized by a positive enthalpic contribution of + 9.36 kcal/mol 
(i.e., -'Hb in Figs. 3A and 4A). Since Eq. (4) represents the direct titration of MalB with SDS 
micelles, the enthalpic term corresponds to 'Hb = -9.06 kcal/mol (Figs. 3B and 4B). Thus, for 
the extraction of MalB from its heparin complex by SDS micelles an endothermic contribution 
of +0.30 kcal/mol (viz, +9.36 Ȃ 9.06 kcal/mol) is estimated, which matches the experimental 
+0.23 kcal/mol directly measured by ITC, as discussed above (Fig. 4C). The nice agreement 
between the results obtained from the model of SDS-driven MalB decomplexation from 
heparin and the relevant experimental data, means we can conclude that the underlying 
assumption that two processes described by Eqs. (3) and (4) indeed take place in successive 
steps. 
3.3. Steered molecular dynamics (SMD) and umbrella sampling (US) of MalB/SDS micelle 
binding 
To obtain a molecular view of the ITC data discussed in Section 3.2, we performed computer-
based simulations by using SMD and US simulations. In our case, SMD is used first to pull out 
MalB from heparin (see Supplementary Material Movie1) and then to drive its binding onto a 
SDS micelle (Supplementary Material Movie2), by applying a guiding potential along a 
reaction coordinate ], and is subsequently employed to generate the initial coordinate for the 
umbrella sampling computations. Upon US simulations to enhance extensive sampling along 
the reaction coordinate, the potential of mean force (PMF) of the binding/unbinding process 
can be constructed. 
Figure 5A illustrates the PMF profile as a function of the reaction coordinate ] for the 
unbinding process of MalB from heparin. As seen in this Figure, the PMF continually increases 
as the pulled MalB transits from the bound to the free state, although some bumpy features 
are visible along the pathway. These might be related to the fact that the 5 positive charges on 
MalB are progressively detached from the polyanion and become solvated by water molecules 
and neutralizing counterions. The total free energy difference between the heparin bound and 
unbound state of MalB is 8.10 kcal/mol, in good agreement with the corresponding free 
energy of binding measured by ITC (-7.89 kcal/mol, Fig. 4A). 
 
 Fig_5.tiff  
Fig. 5. PMF profile along the reaction coordinate ] for the process of (A) unbinding of MalB from heparin and (B) 
binding of MalB to a SDS micelle.  
 
Figure 5B displays the PMF (]) behavior for the binding of MalB to the SDS micelle. This 
Figure shows that the corresponding free energy minimum is located on the micellar surface, 
at a distance of ~1.8 nm from the center of its core. As ] is further decreased, the PMF 
increases steadily. This strongly supports the hypothesis formulated in Section 3.2, according 
to which, once bound, the highly positively-charged MalB molecule does not penetrate the 
palisade layer but remains anchored at the oppositely-charged micellar periphery by virtue of 
strong, stabilizing electrostatic interactions. The ultimate evidence of surface binding of MalB 
onto the micellar surface is given by the Dynamic Light Scattering (DLS) experiments (see 
Supporting Information). According to DLS, SDS assembles in spherical micelles with a 
hydrodynamic diameter of ~4 nm (see insert in figure SI3), characterized by a zeta potential 
of -63.2 ± 3.1 mV. Upon MalB interaction, the average hydrodynamic diameter is equal to ~4.8 
nm (see figure SI3) with a zeta-potential of -52.4 ± 3.7 mV, supporting the fact that SDS 
micelles/MalB binding takes place at the SDS micellar surface.  Finally, the computed free 
energy changes associated with the MalB/SDS binding process, i.e., -7.96 kcal/mol, nicely 
matches the corresponding ITC-derived value of -7.42 kcal/mol (Fig. 4B). 
3.4. Binding thermodynamics of MalB to HSA 
One of the most important results previously reported for MalB as a heparin sensor is that, 
despite the fact that electrostatics should govern the interaction between the dye and the 
polyanion, the former is able to recognize heparin even in the presence of high ionic strength, 
and shows a quantitative linear dose-response behavior in serum [7]. Human serum albumin 
is the most abundant (>50%) protein in blood plasma and serves as a depot protein and 
transport protein for numerous endogenous and exogenous compounds. HSA is also the main 
factor in contributing to the colloid osmotic pressure of the blood and has been suggested as a 
possible source of amino acids for various tissues. Indubitably, albumin is the most 
multifunctional transport protein and plays an important role in the transport and deposition 
of a variety of endogenous and exogenous substances in blood [56]. For these reasons, HSA 
has been considered as a simplified model in studying interaction and binding of drugs and 
small molecules with plasma proteins.  
Under this perspective, we decided to quantify for the first time the interaction of MalB with 
HSA. To this purpose, we resorted again to a combination of experimental and computational 
methods. Figure 6A reports the ITC results of the MalB/HSA binding, while panel B of the 
same Figure shows the comparison between the main dye/protein thermodynamic 
parameters as derived from ITC and MM/PBSA-based molecular dynamics simulations. 
 
 Fig_6.tiff  
Fig. 6. (A) Integrated ITC profiles for MalB binding with HSA with in 10 mM Tris HCl and physiological ionic 
strength (150 mM NaCl). T = 25 °C. The solid red line is data fitting with a one-set-of-sites model. The insert in 
panel A shows the corresponding ITC raw data. Experiments were run in triplicate. (B) Comparison of ITC-
derived (colored bars) and in silico predicted (white bars) thermodynamic parameters for MalB binding with 
HSA. 
 
Several considerations can be drawn from the analysis of the data reported in Fig. 6. First, 
MalB is endowed with a substantially lower experimental affinity for HSA ('Gb = -5.99 
kcal/mol) than for heparin ('Gb = -7.89 kcal/mol) or SDS ('Gb = -7.42 kcal/mol) (see Fig. 4). 
The enthalpic change upon MalB/HSA complex formation is favorable (-7.05 ± 0.12 kcal/mol) 
whereas the entropy change opposes binding (-1.06 kcal/mol) (Fig. 6B). The conformational 
entropy change is commonly unfavorable in protein-ligand binding event, as the binding 
process involves the loss of configurational degrees of freedom for both the drug molecule 
and the protein. However, the entropic penalty paid by the small dye upon protein binding is 
largely compensated by the corresponding enthalpic gain (Fig. 6B), thereby confirming the 
enthalpic-driven nature of the binding mechanism of MalB to human serum albumin. From 
the computational standpoint, MalB docking onto HSA (Fig. 7, left panel) followed by free 
energy of binding scoring in the framework of the MM/PBSA methodology results in a 
calculated ȟ
b,comp value in excellent agreement (-5.63 kcal/mol) with the corresponding ITC-
derived experimental data (-5.99 kcal/mol), as illustrated in Fig. 6B. The enthalpic nature of 
MalB/HSA is confirmed computationally (-13.82 kcal/mol), as is the unfavorable contribution 
from entropy variation upon binding (-8.19 kcal/mol). It is important to observe here that  ȟb  ȟb are normally overestimated in MM/PBSA calculations [37], as in the 
present case; yet, a parallel shift is generally observed between experimental and computed ȟ-ȟǡǡ
value. The analysis of the MD trajectory for the MalB/HSA complex shows that the dye is 
engaged in two permanent salt bridges, involving the negatively charged side chains of 
residues Glu379 and Glu593 on the protein side and one guanidinic and one tertiary amines of 
the dye, respectively (Fig. 7, right panel). The intermolecular complex is further stabilized by 
two hydrogen bonds that, in a symmetrical fashion, link the second guanidinic and tertiary 
amines to the side chains of Asn383 and Gln394. Finally, residues Leu384, Leu391, and 
Ala403 contribute favorable hydrophobic interactions to dye/protein binding (Fig. 7, right 
panel). 
In aggregate, these data quantitatively support our previous evidence [7], according to which 
MalB can overcome one of the major challenges for heparin sensors (i.e., working in complex 
biological fluids), ultimately making it superior to some other approaches. 
Fig_7.tiff  
Fig. 7. (Left) Overall space filling representation of the HSA molecular surface (light blue) and MalB (gray 
spheres) docked into the protein binding site. (Right) Details of MalB in the HSA binding pocket. The protein 
secondary structure is portrayed in a light blue-ribbon style, while MalB is shown as atom-colored sticks-and-
balls (C, gray; N, blue; O, red; S, yellow). The side chains of the HSA residues mainly involved in MalB binding are 
shown as colored sticks, colored according to the underlying interactions (salt bridges, sea green; hydrogen 
bonds, sandy brown; hydrophobic interactions, firebrick). Hydrogen atoms, counterions, and water molecules 
are omitted for clarity. 
 
4. Conclusions 
Heparin, one of the most negatively charged biopolymers, plays a critical role in the regulation 
of blood coagulation, cell growth, and immune response. Moreover, overdose of heparin 
frequently induced severe side effects such as hemorrhage, thrombocytopenia, and 
osteoporosis. Thus, the selective and sensitive detection of heparin, is of great importance in 
general medicine and clinical settings. In recent years, our group has developed Mallard Blue 
(MalB) [7], a new heparin-binding dye that binds heparin in highly competitive media, 
including water with high levels of competitive electrolyte, buffered aqueous solution and 
human serum, and simply reports on heparin levels by a significant change in its UV-visible 
spectroscopic profile. However, several aspects remain to be explored about the interaction of 
MalB with its target polyanion, and their unveiling will undoubtedly influence how MalB will 
be eventually used in biomedical and pharmacological contexts.  
In this work, we investigated some of these unexplored issues, namely the thermodynamics of 
binding between MalB and heparin, and the eventual negative interference by the most 
abundant plasma proteins, namely human serum albumin (HSA), in the MalB/heparin 
complex formation. Also, in analogy with what is observed for, e.g., DNA and small 
intercalating molecules, we deemed it interesting to study the competition for MalB binding 
by other polyanions, such negatively-charged sodium dodecyl sulfate (SDS) micelles. To this 
purpose, we adopted an integrated approach based on a combination of experimental and 
computational technique. 
The results obtained from the application of UV-visible spectroscopy methods allowed us to 
establish that, in a common buffer system (150 mM NaCl/10 mM Tris HCl), MalB efficiently 
binds to both heparin and SDS; yet, SDS is able to extract MalB from its complex with heparin 
when the surfactant is in its self-assembled form (Fig. 2). Accordingly, in this paper we 
demonstrate, for the first time, that small, positively charged molecules bound to heparin, the 
most negatively charged polyanion existing in nature, can be "sequestrated" by anionic 
nanomicelles in a way that utterly resembles that seen for DNA. Moreover, given the 
fundamental electrostatic nature of MalB/SDS interactions, once bound the dye remains 
anchored to the micellar surface and does not penetrate into the micelle palisade layer, as 
further confirmed by computational results. Indeed, the minimum of the potential of mean 
force for MalB/SDS binding is located at a distance matching the radius of the surfactant 
micelle (1.80 nm), and further pulling of MalB towards the center of the micelle results in a 
steep increase of the free energy (Fig. 5). UV-vis results are supported by isothermal titration 
calorimetry (ITC) measurements, according to which heparin and SDS have similar affinity for 
the dye, and in both cases favorable enthalpy variations drive the underlying processes (Fig. 
4). On the other handǡ  ǲǳ  alB from heparin by SDS micelles is 
thermodynamically feasible since the major driving force of the process is purely entropic in 
nature, with the enthalpies of binding to each of these polyanions effectively canceling one 
another out. Finally, the investigation of the interaction between MalB and human serum 
albumin (HSA) reveals that the dye is endowed with substantially less affinity for the most 
abundant plasma proteins compared with its affinity for heparin (Fig. 6), confirming the 
ability of this heparin dye to work in complex physiological environments. 
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Abstract 
Heparin is a sulfated glycan widely used as anticoagulant in medicine. Mallard Blue (MalB), a small cationic dye 
developed in our laboratories, is able to detect heparin in serum and plasma in a dose-response manner, with 
performance superior to its direct competitors. However, many aspects of MalB/heparin binding still remain to 
be explored which, once solved, may foster the clinical use of MalB. Among these, the characterization of the 
energetics that drives the MalB/heparin binding process, the competition for MalB binding by other polyanions 
(e.g., negatively-charged surfactant micelles), and the interaction of MalB with serum proteins are of particular 
interest. This work fills this gap by means of a combination of experimental investigations (UV-visible 
spectroscopy and isothermal titration calorimetry), and computational approaches based on molecular 
dynamics (MD) simulation techniques. In combination, the results obtained show that MalB efficiently binds to 
both heparin and SDS, with the binding being enthalpic in nature; yet, SDS is able to extract MalB from its 
complex with heparin when the surfactant is in its self-assembled form, the driving force underlying SDS-
induced MalB/heparin de-complexation being entropic in nature as the two enthalpies of binding effectively 
cancel each other out. Once bound to SDS, the dye remains electrostatically bound to the micellar surface and 
does not penetrate the micelle palisade layer, as verified by steered molecular dynamics/umbrella sampling 
simulations. Finally, the affinity of MalB for human serum albumin (HSA), the most abundant plasma protein, is 
found to be lower than that for heparin, confirming the ability of the dye to work in complex physiological 
environments. 
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Highlights 
 
x Mallard Blue (MalB) is one of the best dyes for heparin sensing  
x MalB binding to heparin is enthalpy-driven, with a small entropic penalty 
x SDS micelles bind MalB with an affinity similar to heparin, and can decomplex MalB from heparin as a result 
of a favorable entropic contribution 
x MalB binds only weakly to plasma proteins supporting its use in complex biological fluids 
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1. Introduction 
Heparin, a linear polysaccharide consisting of repeating units of 2-O-sulfated iduronic acid 
and 6-O-sulfated, N-sulfated glucosamine (IdoA(2S)-GlcNS(6S), Fig. 1 left) - is one of the most 
charge-dense naturally occurring polyanion in biological systems [1]. Heparin has been used 
as an anticoagulant since 1935 to both treat and prevent the deep vein thrombosis that can 
result from large surgery, blood transfusions, or dialysis. As a result of its clinical importance, 
there has been a surge of interest in developing heparin sensors which can directly detect 
heparin chains within a complex biological sample (that is, measure a true concentration) 
rather than rely on an activity measurement within plasma or serum (units of anticoagulant 
activity). Perhaps the leading strategy has been the development of cationic indicator dyes 
which can quickly report on heparin spectroscopically. In this respect, several molecules such 
as Azure A [2,3], Alcian Blue [4], Methylene Blue [5], Heparin Blue and Heparin Orange [6] Ȃ 
which all exhibit UV response to heparin Ȃ have historically been employed. Yet, while these 
cationic dyes work well in noncompetitive environments, many of them lose efficiency a) in 
the presence of other agents (e.g., plasma proteins) that directly interfere with their heparin 
noncovalent binding and b) as electrolytic competition increases.  
In the quest for alternative heparin sensors that can quantitatively and reliably perform under 
physiological conditions, in 2013 our group synthesized Mallard Blue (MalB, Fig. 1 right), a 
thionine-di-arginine molecule that can be readily obtained via a coupling reaction between 
Tri-Boc-protected arginine and thionine acetate followed by Boc deprotection [7].  
 
Fig_1.tiff  
Fig. 1. Molecular model of the predominant average repeat unit of heparin (left) and of Mallard Blue (MalB, 
right). In each structure, the molecules are shown as atom-colored sticks-and balls (C, gray; O, red; N, blue; S, 
yellow; H, white). Na+ and Cl- counterions are portrayed as purple and green spheres, respectively.  
 
In the same study [7], we established that MalB is able to detect heparin in serum and plasma 
in a dose-response manner, its superior performance with respect to the direct competitor 
Azure A, its heparin specificity and, likely its most interesting and promising property, its 
resistance to high ionic strength (e.g., 150 mM NaCl), despite the fact that electrostatic forces 
govern its interaction with the polyanion. Interestingly, the excellent sensing properties of 
MalB under physiologically conditions were the subject of a positive News and Views article 
which appeared in Nature Chemistry in the same year [8].  
Under this promising scenario, however, many aspects still remain to be explored which, once 
solved, may foster the clinical use of MalB. Among these, the characterization of the energetics 
that drive the MalB/heparin binding process, the competition for MalB binding by other 
polyanions (e.g., negatively-charged surfactant micelles), and the interaction of MalB with 
serum proteins still remain to be performed. This work aims to fill this gap by means of a 
combination of experimental investigations, based on UV-visible spectroscopy and isothermal 
titration calorimetry (ITC), and computational approaches, relying on molecular dynamics 
(MD) simulation techniques. 
Specifically, since the interaction of MalB with heparin has never been fully characterized so 
far, either from a spectrometric or from a thermodynamic point of view, we first report and 
discuss the spectroscopic and thermodynamic behavior for MalB binding to heparin and 
compare them with that obtained for negatively-charged micelles generated by the self-
assembly of a conventional anionic surfactant sodium dodecyl sulfate (SDS). The idea 
underlying these experiments is that, given the predictable electrostatic nature of 
heparin/MalB interaction, highly oppositely-charged micelles may compete with the 
polysaccharide and promote MalB dissociation with subsequent sequestration. Indeed, 
micelle-ǲextractionǳbound ligands from polyanions is a competitive phenomenon, 
particularly in the case of DNA (e.g., drugs/mutagens DNA de-intercalation). However, the 
energy cost for such processes is still not properly understood. Therefore, we deemed it very 
interesting to investigate this particular aspect in case of MalB. These experiments are 
paralleled by computational investigations based on steered molecular dynamics [8-12], 
which allow us to mimic MalB unbinding from heparin and subsequent association with SDS 
micelles at a molecular level.  
Next, we present the results of binding thermodynamics of MalB to the most representative 
plasma protein, human serum albumin (HSA), and resort again to atomistic MD simulations in 
the Molecular Mechanics/Poisson-Boltzmann framework of theory [see 13-16 and references 
therein] to identify the molecular determinants underlying its interaction with the heparin 
sensor. 
 
2. Materials and Methods 
All chemicals were purchased from Sigma Aldrich, and used without further purification. 
Mallard Blue, heparin and human serum albumin were available from our previous work [7, 
17-22]. 
2.1. UV-visible spectroscopy 
UV-visible absorbance was measured on a DeNovix DS11-FX spectrophotometer (DeNovix 
Inc., Wilmington, DE, USA). All MalB solutions were incubated at 50°C for 24 hours prior to 
use and stored in the dark. For the MalB/heparin binding, solutions of MalB (125 PM) in 150 
mM NaCl and 10 mM Tris HCl were incubated with solutions of heparin at progressively 
increasing concentrations in the same buffer (9, 17, 34, 67.5, 125, 250, 500, and 1000 PM). For 
MalB/SDS binding, a series of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, and 5 mM) were added to 
the MalB solutions (125 PM, 150 mM NaCl/10 mM Tris HCl). The range of SDS concentrations 
was selected in order to consider surfactant systems below and above their CMC (1.2 mM, see 
below). For SDS/MalB binding in the presence of heparin, a presoaked MalB/heparin solution 
was prepared (125 PM MalB/150 PM heparin, which ensures complete binding, [7]) and a 
series of SDS solutions (0.25, 0.5, 1, 1.5, 2, 3, 5, and 10 mM) were added. All experiments were 
carried out at 25 °C and performed in triplicate. The absorbance at 615 nm was recorded after 
each addition.  
2.2. Isothermal titration calorimetry (ITC) 
2.2.1. Binding of MalB to heparin, SDS micelles, and SDS-driven MalB extraction from heparin. 
ITC experiments were conducted using MicroCal PEAQ-ITC calorimeter (Malvern, UK) at 25°C.  ? ? ?ɊǤ All experiments were conducted in a backward manner, that is, 
by step-by-step injections of a constant volume of concentrated heparin or SDS solutions into 
the calorimetric cell containing buffer (150 mM NaCl/10 mM Tris HCl, pH 7.4), or buffered 
solutions of MalB, respectively. For SDS-driven MalB extraction from heparin assay, a buffered 
MalB solution in large excess of heparin (to ensure complete MalB/heparin binding) in the 
cell was used instead. Specifically, for SDS CMC determination, a  ?Ɋ of SDS 
solution (60 mM) was repeatedly injected (37 times) into the reaction cell at 150 s intervals. 
For MalB binding by heparin, a polyanion solution (2 mM) was  ? ? ?Ɋ
at 150 s intervals, while the MalB concentration in the calorimeter cell was 125 PM. For 
MalB/SDS binding, a 1 mM solution of MalB in the cell was titrated  ? ? ?Ɋ
a 300 mM SDS solution at 150 s intervals, such that the concentration of SDS was always 
above the CMC, and allowing us to make the assumption that the micelles remained intact 
throughout the experiment. For the MalB/heparin extraction by SDS micelles, the calorimeter 
cell was filled with a pre complexed MalB/heparin solution (1 mM/5 mM), and titration was 
performed with a 300 mM solution   ȋ ? ?    ? Ɋ     ? ? ? ȌǤ All 
solutions and buffers were degassed for 30 min at room temperature under stirring at 750 
rpm prior to each experiment. After careful washing, the cell was pre-rinsed with a portion of 
the buffer, MalB, or MalB/heparin solutions, respectively.  Upon filling the cell and syringe, 
stirring was turned on and each system was allowed to thermally equilibrate for 30 minutes. 
The heat signal resulting from mixing, dilution effects and liquid friction were further 
confirmed by control experiments (data not shown); accordingly, they were subtracted from 
the relevant data sets to yield the corrected integrated data. All experiments were run in 
triplicate. 
2.2.2. Binding of MalB to HSA 
For this ITC experiment, the instrument cell was filled with a 50 PM buffered (150 mM 
NaCl/10 mM Tris HCl, pH 7.4) solution of HSA. Titration was performed with a 500 PM 
buffered solution of MalB, added in 19 portions of 1 PL, with time intervals of 150 s. 
2.3. Molecular simulations 
2.3.1. Model building, refinement and simulation details 
All simulations discussed in this work were carried out using the AMBER16 suite of programs 
[23], the GAFF force field [24] and performed with the GPU version of pmemd (pmemd.cuda) 
in AMBER16 on our MOSE GPU/CPU cluster. AMBER16 is the state of the art simulation 
platform universally recognized and adopted for simulating biological systems and their 
interactions with soft matter and small molecules. A SDS micelle (consisting of 60 surfactant 
monomers) was built using the Micelle Maker server [25], and optimized, following a 
consolidated procedure for self-assembly nanostructures [17-22,26-30]. The initial, optimized 
structures of heparin, MalB, heparin/MalB complex and ligand-free human serum albumin 
(HSA) were taken from our previous work [7,9,14,17-22]. 
Docking of MalB to HSA was accomplished by adapting a procedure described in details in 
[13,15,16,31-34 and references therein]. Briefly, docking experiments were performed with 
Autodock 4.2/Autodock Tools 1.4.6 [35]. The resulting docked conformations were clustered 
and visualized; then, only the molecular conformation satisfying the combined criteria of 
having the lowest (i.e., more favorable) Autodock energy and belonging to a highly populated 
cluster was selected to carry forward for further modeling. The MalB/HSA complex obtained 
from the docking procedure was further refined in Amber 16 using the quenched molecular 
dynamics (QMD) method as previously described [36-38].  
The optimized structures of the SDS micelle, heparin/MalB complex, and MalB/HSA complex 
were immersed in a box of TIP3P water molecules [39]. The choice of the TIP3P model is 
based on the fact that it is the best compromise between accuracy description of the water 
behavior and computational time required; moreover, it has been specifically developed and 
parametrized to simulate hydrated environments of biological macromolecules, surfactants 
and small organic molecules. The dimensions of each simulation box were chosen in order to 
ensure a 1 nm solvation shell around each solute structure. Suitable amounts of Na+ and Cl- 
ions required to achieve solution neutrality and realize a physiological ionic strength of 0.15 
M were added to each system. The resulting hydrated structures were then subjected to an 
initial Steepest Descent (SD)/Conjugated Gradient (CG) minimization with 5.0 kcal/(mol ǒ 2) 
restraint on the solute (solvent relaxation), followed by another round of CG minimization 
without restraints in order to eliminate all bad contacts between water molecules and each 
solute. 
Next, each minimized structure was subjected to molecular dynamics (MD) simulations in the 
canonical (NVT) ensemble. During these 100 ps of MD, each system was gradually heated and 
relaxed to 25°C. The SHAKE algorithm [40] was applied to all covalent bonds involving 
hydrogen atoms. An integration time step of 2 fs was adopted together with the Langevin 
thermostat for temperature regulation (collision frequency = 2.0 ps-1) [41]. The final heating 
step was followed by 50 ns of MD equilibration in the isochoric/isothermal (NPT) ensemble. 
Pressure control was exerted by coupling the system to a Berendsen barostat (pressure 
relaxation time 2 ps) [42]. The Particle Mesh Ewald (PME) method [43Ȑ   - - ? ?ǒ . To generate the starting configuration for steered molecular dynamics simulations 
(Section 2.3.2), a frame of the SDS micelle and of the MalB/heparin complex was extracted 
from the corresponding equilibrated MD trajectories. The entire equilibrated MD run of the 
MalB/HSA complex was used in the determination of dye/protein free energy of binding 
(section 2.3.3).  
2.3.2. Steered molecular dynamics (SMD) and Umbrella sampling (US) simulations 
The unbinding process of MalB from heparin and the binding event between MalB and the 
SDS micelle were simulated using a combination of steered molecular dynamics (SMD) [9-12] 
and umbrella sampling (US) simulations [44]. In the first case, the MalB/heparin complex 
structure extracted from the corresponding equilibrated MD simulations was solvated with a 
TIP3P water [39] cubic box, and ions and counter ions were added to neutralize the system 
and reach the physiological ionic strength (150 mM NaCl). In the second case, the optimized 
SDS micelle and a molecule of MalB were placed in simulation cell at an initial distance of 
approximately 5 nm. The resulting system was solvated using the same solvent system 
adopted for the MalB/heparin complex.  After each system equilibration (1 ns of NVT/NPT 
MD simulation), SMD runs were performed, and were next used to extract the initial 
coordinates for umbrella sampling simulations along the unbinding/binding pathway, 
respectively. A pulling force with a virtual spring constant of 50 kcal (mol Å2)-1 was imposed 
on the ligand center of mass and the center of mass of the SDS micelle/heparin in the 
unbinding/binding simulations, and the speed was 5 Å ns-1 based on considerations of 
sampling accuracy and computational efficiency. The reaction coordinate for the umbrella 
sampling simulations, ], is defined as the distance between the MalB center of mass (COM) 
and the COM of heparin when pulling MalB out of the heparin complex, and between the COM 
of MalB and the COM of the SDS micelle when pulling MalB towards the SDS micelle. During 
both SMD and US simulations, the heparin/SDS micelle initial structures were retained in 
their initial configurations applying a small constraint force of 5 kcal (mol Å2)-1 on the 
coordinates of the heavy atoms of heparin for the unbinding simulations, and on the two 
terminal carbons of each SDS chain in the binding simulations.  
To perform US simulations, MalB position probability distributions along the reaction 
coordinate were extracted from the corresponding SMD simulations. US method adopts a 
biased potential function imposed on the structure generated by the SMD along ], according 
to the following equation: ǯȋ]) = U(]) + W(])           (1) 
where U(]) is the potential function and W(]) is a quadratic-form weighting function: 
W(]) = K (] Ȃ ]0)2/2           (2) 
in which K is the harmonic force constant and ]0 is the harmonic potential center.  
In this work, each path was subdivided in 80 windows (spacing 0.8 Å), enough to push the 
MalB inside the SDS micelle in the binding simulation, and to bring the MalB fairly far away 
from heparin in the unbinding one. An equilibration time of 1 ns was adopted for each 
window, and data collection lasted 4 ns per window, yielding a total data collection time of 
320 ns. A value of K = 5 kcal/mol was set to restrain ] in all simulations. The weighted 
histogram analysis method (WHAM) [45] was used to unbias simulations and to retrieve the 
PMF. Errors were estimated by the bootstrapping analysis implemented in the WHAM 
package [46]. 
2.3.3. Mallard Blue/human serum albumin free energy of binding calculations 
The free energy of binding between MalB and HSA was obtained by applying the Molecular 
Mechanics/Poisson Boltzmann Surface Area (MM/PBSA) approach [13-16]. This 
computational technique employs snapshots taken from MD trajectories to estimate the 
average interaction energies based on the solute molecular mechanics internal energy and 
solvation energy (constituting the enthalpic term), and entropy variation. The solvation term 
is calculated solving the Poisson-Boltzmann equation [47] while 'Gnp can be obtained via the 
semi-empirical expression [48]: 'Gnp = J × SASA + E, in which SASA is the solvent accessible 
surface area of the molecule, J is the surface tension parameter (0.00542 kcal/Å2/mol), and E 
= 0.92 kcal/mol. Finally, the entropic contribution is calculated via normal mode of harmonic 
frequencies [49] obtained from a subset of minimized snapshots taken from the 
corresponding MD trajectories. For the analysis of the energy of interaction between HSA and 
MalB, energy values were averaged over 200 frames taken during equally spaced time 
intervals along the last 15 ns of the MD production steps. Normal mode analysis was carried 
out on a subset of 15 minimized MD snapshots evenly extracted from the relevant trajectory 
time frame used for energy calculations. 
 
3. Results and discussion 
3.1. UV-visible spectroscopy assays 
The first experiment was carried out to investigate the binding of MalB to SDS using UV-
visible spectroscopy. The insert in Fig. 2A shows a representative set of the UV-visible spectra 
of MalB in the absence and in the presence of increasing concentration of SDS (the full curve 
set is shown in Fig. SI1). As already reported in our previous investigation [7], MalB in 150 
mM NaCl/10 mM Tris HCl buffer produces an absorption peak at 615 nm; upon addition of 
SDS, the maximum absorbance initially decreases and then increases with increasing 
surfactant concentration. This non-monotonic behavior can be better appreciated by plotting 
the relative change in absorption intensity (I/I0, where I and I0 are the peak absorption values 
in the presence and absence of SDS, respectively), as illustrated in Fig. 2A.  
 
Fig_2.tiff 
Fig. 2. Relative change in UV-visible absorbance intensity (I/I0) of (A) MalB as a function of SDS concentration, 
(B) MalB as a function of heparin concentration, and (C) heparin/MalB complex as a function of SDS 
concentration in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). In all experiments, [MalB] = 
125 PM. The corresponding absorbance spectra is shown in the relative Figure insets. For clarity, only a 
representative set of the corresponding absorbance spectra is shown in the inset of panel A (see Fig. SI1 for the 
full curve set). 
 
We see from this Figure that, for small additions of SDS (i.e., [SDS] < CMCSDS), I/I0 attains 
values lower than 1. This initial quenching of the MalB UV-visible absorbance intensity can be 
attributed to the interaction of MalB molecules with SDS surfactant in its monomeric form, in 
agreement with previous literature reports for other cationic dyes, e.g., Nile Blue [50] and 
phenosafranine [51]. As [SDS] approaches CMCSDS in the adopted buffer conditions (CMCSDS = 
1.02 mM in 150 mM NaCl/10 mM Tris HCl, see Fig. SI2), I/I0 rapidly increases and then levels-
off for surfactant concentration values > 3 mM (Fig. 2A). The substantial increase in the 
absorption spectrum intensity of MalB at higher SDS concentrations is indicative of a tighter 
binding of the dye with SDS micelles driven by electrostatic forces between the highly 
negative micellar surface and the positive charges present on the molecular dye, which places 
MalB into a different environment. [52-54].  
Figure 2B shows the profile of I/I0 for the interaction between MalB and heparin. In this case, 
the initial electrostatic polyanion/MalB interactions result in a plummet of the MalB UV-
visible absorption intensity, followed by a considerably less pronounced decrease of I/I0 vs. 
[Heparin] once all polysaccharide binding sites become saturated by dye binding (i.e., 125 PM 
< [Heparin] < 250 PM). Interestingly, a similar behavior has been reported for Nile Blue 
binding to DNA [50,55], suggesting that common mechanisms may underlie the interactions 
of different cationic molecules with the two seemingly different, negatively charged 
biomacromolecules. 
When SDS solutions are added to a pre-formed MalB/heparin complex, the UV-visible spectra 
reported in Fig. 2C are obtained. The initially flat curve of I/I0 as a function of [SDS] rapidly 
increases for [SDS]  ? CMCSDS and ultimately plateaus for [SDS] > 2.5 PM. In this last surfactant 
concentration range, the absorption intensity values correspond to those observed for MalB 
in the pure SDS micellar environment, strongly supporting the notion that the dye, no longer 
bound to heparin, has been complexed by the surfactant self-assembled spherical micelles1. 
3.2. Isothermal titration calorimetry (ITC) assays 
To experimentally quantify - for the first time - the binding thermodynamics between MalB 
and heparin, to confirm the spectroscopic evidences of MalB/SDS micelle interactions, and to 
verify the ability of SDS micelles to extract MalB from heparin, we resorted to ITC 
measurements, as shown in Fig. 3. 
The binding of MalB to heparin (Fig. 3A) is strongly exothermic ('Hb = -9.36 ± 0.24 kcal/mol), 
while a small, negative entropy change opposes dye/polyanion interaction (T'Sb = -1.47 
kcal/mol). Accordingly, MalB/heparin complex formation is thermodynamically favored, with 
                                                        
1 It should be noted that the I/I0 value appears larger in Fig. 2C than 2A because the starting point of the 
experiment, and hence the value of I0, is different. In Fig. 2A the starting point I0 value corresponds to 
uncomplexed MalB, whereas in Fig. 2B, the starting point I0 corresponds to MalB bound to heparin. 
a free energy of binding 'Gb value of Ȃ 7.89 kcal/mol (see Fig. 4A). The large, negative 
enthalpy variation observed in MalB/heparin complex formation is comparable to that 
observed for, e.g., small molecule/DNA or drug/protein binding [9-22,26-34], and can be 
ascribed to the formation of a network of stabilizing non-specific intermolecular interactions 
(i.e., electrostatic, hydrogen bonds, salt bridges,) between the two molecular entities. The 
small and unfavorable entropic term is also quite characteristic of these processes, since 
macromolecule/ligand hydrophobic interactions and water/ion release into the bulk cannot 
compensate for the loss in degree of freedom of experienced by the dye/polyanion upon 
binding.  
 
     Fig_3.tiff 
Fig. 3. Representative integrated ITC profiles for titration of (A) MalB with heparin, (B) MalB with SDS, and (C) 
MalB/heparin complex with SDS in 10 mM Tris HCl and physiological ionic strength (150 mM NaCl). T = 25 °C. 
The solid red lines are data fitting with a sigmoidal function. The inserts in each panel show the corresponding 
ITC raw data. All experiments were run in triplicate. 
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Fig. 4. ITC-derived thermodynamic parameters ('Hb, full color; T'Sb, square pattern; 'Gb, diagonal line pattern) 
for (A) MalB binding with heparin, (B) MalB binding with SDS, and (C) extraction of MalB from the MalB/heparin 
complex with SDS.  
 
The interaction of SDS micelles with MalB (Fig. 3B) is also enthalpically driven ('Hb = -9.06 ± 
0.19 kcal/mol) and, as for MalB/heparin binding, is characterized by a small entropic penalty 
(T'Sb = - 1.64 kcal/mol), resulting in an overall favorable binding free energy 'Gb of -7.42 
kcal/mol (Fig. 4B). The fact that the MalB/SDS has a substantial enthalpic nature supports the 
fact that hydrophobic interactions contribute only in minimal part to this specific dye/micelle 
binding, and electrostatic forces play the leading role. This, in turn, suggests that, once bound, 
MalB prefers to reside in the micellar outer Stern layer rather than locating itself into the 
palisade layer or deep inside the micellar core (see Section 3.3).  
Finally, ITC measurements reveal that, when SDS micelles are added to a MalB/heparin 
complex solution, the thermodynamic nature of the underlying process is opposite with 
respect to that described above (Fig. 3C). Indeed, while an almost negligible, endothermic 
contribution is measured ('Hb = + 0.23 ± 0.04 kcal/mol), the driving force for MalB extraction 
from heparin by SDS micelles results from the strong, positive entropic variation (T'Sb = + 
6.25 kcal/mol), which ultimately determines the overall negative value of the free energy ('Gb 
= -6.02 kcal/mol) (see Fig. 4C). The increase in system entropy can be attributed to several, 
concomitant factors, including i) an increase in degrees of freedom of heparin after MalB 
complexation, ii) the disruption of hydrogen bonds and electrostatic interactions between 
water molecules/counterions and the micellar surface upon MalB binding, and iii) their 
subsequent release into the bulk solvent.  
In order to model the process of MalB extraction from heparin by the anionic surfactant 
micelles the following two-step model can be assumed: 
 ሺܯ݈ܽܤȀܪ݁݌ܽݎ݅݊ሻ௛௬ௗ௥ ֖  ሺܯ݈ܽܤሻ௛௬ௗ௥ ൅ ሺܪ݁݌ܽݎ݅݊ሻ௛௬ௗ௥       (3) ሺܵܦܵ݈݈݉݅ܿ݁݁ݏሻ௛௬ௗ௥ ൅ ሺܯ݈ܽܤሻ௛௬ௗ௥ ֖  ሺܯ݈ܽܤ ܵܦܵ݈݈݉݅ܿ݁݁ݏ ? ሻ௛௬ௗ௥      (4) 
 
in which all different species are considered in their hydrated form in the relevant buffer. The 
approach is obviously a rough simplification of reality, as i) it assumes that Eqs. (3) and (4) 
represent independent events and ii) additional steps associated with these two major events 
either do not contribute significantly to the overall process or their effects are accounted for 
by the equilibrium thermodynamic parameters. Under this hypothesis, and with the further 
assumption that each binding process is reversible, the unbinding of MalB from heparin (i.e., 
Eq. (3)) should then be characterized by a positive enthalpic contribution of + 9.36 kcal/mol 
(i.e., -'Hb in Figs. 3A and 4A). Since Eq. (4) represents the direct titration of MalB with SDS 
micelles, the enthalpic term corresponds to 'Hb = -9.06 kcal/mol (Figs. 3B and 4B). Thus, for 
the extraction of MalB from its heparin complex by SDS micelles an endothermic contribution 
of +0.30 kcal/mol (viz, +9.36 Ȃ 9.06 kcal/mol) is estimated, which matches the experimental 
+0.23 kcal/mol directly measured by ITC, as discussed above (Fig. 4C). The nice agreement 
between the results obtained from the model of SDS-driven MalB decomplexation from 
heparin and the relevant experimental data, means we can conclude that the underlying 
assumption that two processes described by Eqs. (3) and (4) indeed take place in successive 
steps. 
3.3. Steered molecular dynamics (SMD) and umbrella sampling (US) of MalB/SDS micelle 
binding 
To obtain a molecular view of the ITC data discussed in Section 3.2, we performed computer-
based simulations by using SMD and US simulations. In our case, SMD is used first to pull out 
MalB from heparin (see Supplementary Material Movie1) and then to drive its binding onto a 
SDS micelle (Supplementary Material Movie2), by applying a guiding potential along a 
reaction coordinate ], and is subsequently employed to generate the initial coordinate for the 
umbrella sampling computations. Upon US simulations to enhance extensive sampling along 
the reaction coordinate, the potential of mean force (PMF) of the binding/unbinding process 
can be constructed. 
Figure 5A illustrates the PMF profile as a function of the reaction coordinate ] for the 
unbinding process of MalB from heparin. As seen in this Figure, the PMF continually increases 
as the pulled MalB transits from the bound to the free state, although some bumpy features 
are visible along the pathway. These might be related to the fact that the 5 positive charges on 
MalB are progressively detached from the polyanion and become solvated by water molecules 
and neutralizing counterions. The total free energy difference between the heparin bound and 
unbound state of MalB is 8.10 kcal/mol, in good agreement with the corresponding free 
energy of binding measured by ITC (-7.89 kcal/mol, Fig. 4A). 
 
 Fig_5.tiff  
Fig. 5. PMF profile along the reaction coordinate ] for the process of (A) unbinding of MalB from heparin and (B) 
binding of MalB to a SDS micelle.  
 
Figure 5B displays the PMF (]) behavior for the binding of MalB to the SDS micelle. This 
Figure shows that the corresponding free energy minimum is located on the micellar surface, 
at a distance of ~1.8 nm from the center of its core. As ] is further decreased, the PMF 
increases steadily. This strongly supports the hypothesis formulated in Section 3.2, according 
to which, once bound, the highly positively-charged MalB molecule does not penetrate the 
palisade layer but remains anchored at the oppositely-charged micellar periphery by virtue of 
strong, stabilizing electrostatic interactions. The ultimate evidence of surface binding of MalB 
onto the micellar surface is given by the Dynamic Light Scattering (DLS) experiments (see 
Supporting Information). According to DLS, SDS assembles in spherical micelles with a 
hydrodynamic diameter of ~4 nm (see insert in figure SI3), characterized by a zeta potential 
of -63.2 ± 3.1 mV. Upon MalB interaction, the average hydrodynamic diameter is equal to ~4.8 
nm (see figure SI3) with a zeta-potential of -52.4 ± 3.7 mV, supporting the fact that SDS 
micelles/MalB binding takes place at the SDS micellar surface.  Finally, the computed free 
energy changes associated with the MalB/SDS binding process, i.e., -7.96 kcal/mol, nicely 
matches the corresponding ITC-derived value of -7.42 kcal/mol (Fig. 4B). 
3.4. Binding thermodynamics of MalB to HSA 
One of the most important results previously reported for MalB as a heparin sensor is that, 
despite the fact that electrostatics should govern the interaction between the dye and the 
polyanion, the former is able to recognize heparin even in the presence of high ionic strength, 
and shows a quantitative linear dose-response behavior in serum [7]. Human serum albumin 
is the most abundant (>50%) protein in blood plasma and serves as a depot protein and 
transport protein for numerous endogenous and exogenous compounds. HSA is also the main 
factor in contributing to the colloid osmotic pressure of the blood and has been suggested as a 
possible source of amino acids for various tissues. Indubitably, albumin is the most 
multifunctional transport protein and plays an important role in the transport and deposition 
of a variety of endogenous and exogenous substances in blood [56]. For these reasons, HSA 
has been considered as a simplified model in studying interaction and binding of drugs and 
small molecules with plasma proteins.  
Under this perspective, we decided to quantify for the first time the interaction of MalB with 
HSA. To this purpose, we resorted again to a combination of experimental and computational 
methods. Figure 6A reports the ITC results of the MalB/HSA binding, while panel B of the 
same Figure shows the comparison between the main dye/protein thermodynamic 
parameters as derived from ITC and MM/PBSA-based molecular dynamics simulations. 
 
 Fig_6.tiff  
Fig. 6. (A) Integrated ITC profiles for MalB binding with HSA with in 10 mM Tris HCl and physiological ionic 
strength (150 mM NaCl). T = 25 °C. The solid red line is data fitting with a one-set-of-sites model. The insert in 
panel A shows the corresponding ITC raw data. Experiments were run in triplicate. (B) Comparison of ITC-
derived (colored bars) and in silico predicted (white bars) thermodynamic parameters for MalB binding with 
HSA. 
 
Several considerations can be drawn from the analysis of the data reported in Fig. 6. First, 
MalB is endowed with a substantially lower experimental affinity for HSA ('Gb = -5.99 
kcal/mol) than for heparin ('Gb = -7.89 kcal/mol) or SDS ('Gb = -7.42 kcal/mol) (see Fig. 4). 
The enthalpic change upon MalB/HSA complex formation is favorable (-7.05 ± 0.12 kcal/mol) 
whereas the entropy change opposes binding (-1.06 kcal/mol) (Fig. 6B). The conformational 
entropy change is commonly unfavorable in protein-ligand binding event, as the binding 
process involves the loss of configurational degrees of freedom for both the drug molecule 
and the protein. However, the entropic penalty paid by the small dye upon protein binding is 
largely compensated by the corresponding enthalpic gain (Fig. 6B), thereby confirming the 
enthalpic-driven nature of the binding mechanism of MalB to human serum albumin. From 
the computational standpoint, MalB docking onto HSA (Fig. 7, left panel) followed by free 
energy of binding scoring in the framework of the MM/PBSA methodology results in a 
calculated ȟ
b,comp value in excellent agreement (-5.63 kcal/mol) with the corresponding ITC-
derived experimental data (-5.99 kcal/mol), as illustrated in Fig. 6B. The enthalpic nature of 
MalB/HSA is confirmed computationally (-13.82 kcal/mol), as is the unfavorable contribution 
from entropy variation upon binding (-8.19 kcal/mol). It is important to observe here that  ȟb  ȟb are normally overestimated in MM/PBSA calculations [37], as in the 
present case; yet, a parallel shift is generally observed between experimental and computed ȟ-ȟǡǡ
value. The analysis of the MD trajectory for the MalB/HSA complex shows that the dye is 
engaged in two permanent salt bridges, involving the negatively charged side chains of 
residues Glu379 and Glu593 on the protein side and one guanidinic and one tertiary amines of 
the dye, respectively (Fig. 7, right panel). The intermolecular complex is further stabilized by 
two hydrogen bonds that, in a symmetrical fashion, link the second guanidinic and tertiary 
amines to the side chains of Asn383 and Gln394. Finally, residues Leu384, Leu391, and 
Ala403 contribute favorable hydrophobic interactions to dye/protein binding (Fig. 7, right 
panel). 
In aggregate, these data quantitatively support our previous evidence [7], according to which 
MalB can overcome one of the major challenges for heparin sensors (i.e., working in complex 
biological fluids), ultimately making it superior to some other approaches. 
Fig_7.tiff  
Fig. 7. (Left) Overall space filling representation of the HSA molecular surface (light blue) and MalB (gray 
spheres) docked into the protein binding site. (Right) Details of MalB in the HSA binding pocket. The protein 
secondary structure is portrayed in a light blue-ribbon style, while MalB is shown as atom-colored sticks-and-
balls (C, gray; N, blue; O, red; S, yellow). The side chains of the HSA residues mainly involved in MalB binding are 
shown as colored sticks, colored according to the underlying interactions (salt bridges, sea green; hydrogen 
bonds, sandy brown; hydrophobic interactions, firebrick). Hydrogen atoms, counterions, and water molecules 
are omitted for clarity. 
 
4. Conclusions 
Heparin, one of the most negatively charged biopolymers, plays a critical role in the regulation 
of blood coagulation, cell growth, and immune response. Moreover, overdose of heparin 
frequently induced severe side effects such as hemorrhage, thrombocytopenia, and 
osteoporosis. Thus, the selective and sensitive detection of heparin, is of great importance in 
general medicine and clinical settings. In recent years, our group has developed Mallard Blue 
(MalB) [7], a new heparin-binding dye that binds heparin in highly competitive media, 
including water with high levels of competitive electrolyte, buffered aqueous solution and 
human serum, and simply reports on heparin levels by a significant change in its UV-visible 
spectroscopic profile. However, several aspects remain to be explored about the interaction of 
MalB with its target polyanion, and their unveiling will undoubtedly influence how MalB will 
be eventually used in biomedical and pharmacological contexts.  
In this work, we investigated some of these unexplored issues, namely the thermodynamics of 
binding between MalB and heparin, and the eventual negative interference by the most 
abundant plasma proteins, namely human serum albumin (HSA), in the MalB/heparin 
complex formation. Also, in analogy with what is observed for, e.g., DNA and small 
intercalating molecules, we deemed it interesting to study the competition for MalB binding 
by other polyanions, such negatively-charged sodium dodecyl sulfate (SDS) micelles. To this 
purpose, we adopted an integrated approach based on a combination of experimental and 
computational technique. 
The results obtained from the application of UV-visible spectroscopy methods allowed us to 
establish that, in a common buffer system (150 mM NaCl/10 mM Tris HCl), MalB efficiently 
binds to both heparin and SDS; yet, SDS is able to extract MalB from its complex with heparin 
when the surfactant is in its self-assembled form (Fig. 2). Accordingly, in this paper we 
demonstrate, for the first time, that small, positively charged molecules bound to heparin, the 
most negatively charged polyanion existing in nature, can be "sequestrated" by anionic 
nanomicelles in a way that utterly resembles that seen for DNA. Moreover, given the 
fundamental electrostatic nature of MalB/SDS interactions, once bound the dye remains 
anchored to the micellar surface and does not penetrate into the micelle palisade layer, as 
further confirmed by computational results. Indeed, the minimum of the potential of mean 
force for MalB/SDS binding is located at a distance matching the radius of the surfactant 
micelle (1.80 nm), and further pulling of MalB towards the center of the micelle results in a 
steep increase of the free energy (Fig. 5). UV-vis results are supported by isothermal titration 
calorimetry (ITC) measurements, according to which heparin and SDS have similar affinity for 
the dye, and in both cases favorable enthalpy variations drive the underlying processes (Fig. 
4). On the other handǡ  ǲǳ  alB from heparin by SDS micelles is 
thermodynamically feasible since the major driving force of the process is purely entropic in 
nature, with the enthalpies of binding to each of these polyanions effectively canceling one 
another out. Finally, the investigation of the interaction between MalB and human serum 
albumin (HSA) reveals that the dye is endowed with substantially less affinity for the most 
abundant plasma proteins compared with its affinity for heparin (Fig. 6), confirming the 
ability of this heparin dye to work in complex physiological environments. 
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